Literature DB >> 24488155

Investigation of retinal nerve fiber layer thickness in patients with neurofibromatosis-1.

Pinar Topcu-Yilmaz1, Burcu Kasim, Hayyam Kiratli.   

Abstract

PURPOSE: To compare the optical coherence tomography (OCT) findings of neurofibromatosis-1 (NF-1) patients with/without optic pathway glioma (OPG) with those of healthy controls.
METHODS: Ten patients with NF-1, 17 patients with NF-1-associated OPGs, and 17 control subjects were included in the study. Retinal nerve fiber layer (RNFL) and macular thickness findings measured with Stratus OCT were compared between the groups.
RESULTS: The average RNFL thickness was significantly lower in the OPG group (76.72 ± 22.16 μm) than in the controls (108.89 ± 9.92 μm) and NF-1 patients without OPGs (111.17 ± 12.13 μm) (p < 0.001). The macular volume was also found to be lower in NF-1 patients with OPG (6.41 ± 0.66 mm(3)) than in the healthy controls (7.19 ± 0.36 mm(3); p = 0.001) and NF-1 patients without OPGs (7.25 ± 0.26 mm(3); p = 0.005). Following this analysis the OPG group was further subdivided into two categories: OPG patients with normal visual acuity (VA) and OPG patients with decreased VA. The statistical analysis was repeated for these four subgroups, revealing that while the decrement in the average RNFL thickness was significant for both OPG groups that in the macular volume was only significant for OPG patients with decreased VA.
CONCLUSION: The results of our study suggest that RNFL thinning can be a helpful marker for the detection of OPGs in NF-1 patients. Larger studies with longitudinal data are required to confirm the role of OCT in the diagnosis and follow-up of these patients.

Entities:  

Mesh:

Year:  2014        PMID: 24488155     DOI: 10.1007/s10384-014-0308-6

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  21 in total

1.  Relationship between retinal nerve fiber layer and visual field sensitivity as measured by optical coherence tomography in chiasmal compression.

Authors:  Helen V Danesh-Meyer; Stuart C Carroll; Rod Foroozan; Peter J Savino; Jennifer Fan; Yannan Jiang; Stephen Vander Hoorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

2.  Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?

Authors:  Darcy H Wolsey; Scott A Larson; Donnel Creel; Robert Hoffman
Journal:  J AAPOS       Date:  2006-08       Impact factor: 1.220

3.  Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials.

Authors:  G T Liu; P Malloy; M Needle; P Phillips
Journal:  Pediatr Neurol       Date:  1995-01       Impact factor: 3.372

4.  Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging.

Authors:  C F Parsa; C S Hoyt; R L Lesser; J M Weinstein; C M Strother; R Muci-Mendoza; M Ramella; R S Manor; W A Fletcher; M X Repka; J A Garrity; R N Ebner; M L Monteiro; R M McFadzean; I V Rubtsova; W F Hoyt
Journal:  Arch Ophthalmol       Date:  2001-04

5.  Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.

Authors:  L J Balcer; G T Liu; G Heller; L Bilaniuk; N J Volpe; S L Galetta; P T Molloy; P C Phillips; A J Janss; S Vaughn; M G Maguire
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

Review 6.  Optical coherence tomography in multiple sclerosis.

Authors:  Elliot Frohman; Fiona Costello; Robert Zivadinov; Olaf Stuve; Amy Conger; Heather Winslow; Anand Trip; Teresa Frohman; Laura Balcer
Journal:  Lancet Neurol       Date:  2006-10       Impact factor: 44.182

7.  Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.

Authors:  Lan Chang; Mays A El-Dairi; Tamiesha A Frempong; Erica L Burner; M Tariq Bhatti; Terri L Young; Fawn Leigh
Journal:  J AAPOS       Date:  2010-12       Impact factor: 1.220

8.  Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history.

Authors:  R Listernick; C Darling; M Greenwald; L Strauss; J Charrow
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

9.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

10.  Follow-up of optic pathway gliomas in children with neurofibromatosis type 1.

Authors:  C Kuenzle; M Weissert; E Roulet; H Bode; S Schefer; T Huisman; K Landau; E Boltshauser
Journal:  Neuropediatrics       Date:  1994-12       Impact factor: 1.947

View more
  5 in total

Review 1.  Pathophysiology, diagnosis, and management of glaucoma associated with Sturge-Weber syndrome.

Authors:  Usman Javaid; Muhammad Hassaan Ali; Samreen Jamal; Nadeem Hafeez Butt
Journal:  Int Ophthalmol       Date:  2017-01-07       Impact factor: 2.031

Review 2.  Optical coherence tomography as a marker of vision in children with optic pathway gliomas.

Authors:  Ana Banc; Cristina Stan; Ioan Stefan Florian
Journal:  Childs Nerv Syst       Date:  2017-08-26       Impact factor: 1.475

3.  Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.

Authors:  Mustafa Hepokur; Ahmet Murat Sarici
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-12       Impact factor: 3.117

Review 4.  Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography.

Authors:  Barmak Abdolrahimzadeh; Domenica Carmen Piraino; Giorgio Albanese; Filippo Cruciani; Siavash Rahimi
Journal:  Clin Ophthalmol       Date:  2016-05-13

Review 5.  Ocular manifestations of Sturge-Weber syndrome: pathogenesis, diagnosis, and management.

Authors:  Flavio Mantelli; Alice Bruscolini; Maurizio La Cava; Solmaz Abdolrahimzadeh; Alessandro Lambiase
Journal:  Clin Ophthalmol       Date:  2016-05-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.